MCK vs OMCL
MCK: McKesson is a healthcare services giant that orchestrates the entire pharmaceutical and medical supply chain—from drug distribution and specialty oncology care to technology platforms that connect patients, pharmacies, and providers. OMCL: Omnicell automates medication management across healthcare settings through storage, dispensing, and intelligence solutions to enable safer, more efficient pharmacy operations.
Side-by-side fundamentals
| Metric | MCK | OMCL | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $814.04 | $40.86 | |
| Market cap as of 2026-07-23 | $96.6B | $1.9B | |
| P/E as of 2026-07-23 | 20.29 | 91.01 | MCK lower |
| PEG as of 2026-07-23 | 1.50 | 2.94 | MCK lower |
| Net margin as of 2026-07-23 | +1.2% | +1.7% | OMCL higher |
| Gross margin as of 2026-07-23 | +3.6% | +43.5% | OMCL higher |
| Operating margin as of 2026-07-23 | +1.5% | +2.8% | OMCL higher |
| ROE as of 2026-07-23 | +39.4% | +1.6% | MCK higher |
| ROA as of 2026-07-23 | +5.7% | +1.0% | MCK higher |
| Debt / equity as of 2026-07-23 | 1.29 | 0.13 | OMCL lower |
| Revenue growth (YoY) as of 2026-07-23 | +12.4% | +7.9% | MCK higher |
| Revenue CAGR (3y) SEC XBRL | +13.4% | -2.9% | MCK higher |
| Dividend yield as of 2026-07-23 | +0.5% | n/a | |
| Dividend streak (yrs) SEC XBRL | 5 | n/a | |
| Beta as of 2026-07-23 | 0.32 | 0.97 | |
| 1-year return as of 2026-07-22 close | +14.7% | +44.6% | OMCL higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.